|
Biomarkers |
Total sample |
No dysfunction |
Asymptomatic dysfunction |
F |
p |
Mild |
Moderate |
LVEF |
Baseline |
61.15 ± 5.85 |
60.84 ± 5.74 |
62.94 ± 5.69 |
59.56 ± 6.95 |
1.235 |
0.296 |
3 months |
58.65 ± 6.47 |
60.15 ± 5.65 |
58.09 ± 5.74 |
48.35 ± 4.47 |
15.944*
|
<0.001*
|
Significance between groups |
|
p1=0.357, p2<0.001*, p3<0.001*
|
|
|
6 months |
58.92 ± 6.66 |
60.33 ± 6.31 |
57.80 ± 5.10 |
50.86 ± 6.62 |
7.708*
|
0.001*
|
Significance between groups |
|
p1=0.342, p2=0.001*, p3=0.041*
|
|
|
LVEDVi |
Baseline |
49.07 ± 12.59 |
48.65 ± 12.81 |
48.42 ± 11.30 |
53.82 ± 14.21 |
0.623 |
0.539 |
3 months |
49.54 ± 11.46 |
49.20 ± 11.75 |
49.99 ± 11.88 |
51.15 ± 9.06 |
0.118 |
0.889 |
6 months |
52.67 ± 12.15 |
51.85 ± 12.15 |
54.20 ± 13.38 |
55.52 ± 10.18 |
0.423 |
0.657 |
LVESVi |
Baseline |
20.04 ± 6.15 |
20.14 ± 6.29 |
18.49 ± 6.05 |
22.71 ± 4.74 |
1.338 |
0.268 |
3 months |
21.09 ± 6.36 |
20.53 ± 6.27 |
20.30 ± 5.70 |
27.24 ± 5.82 |
4.448*
|
0.015*
|
Significance between groups |
p1=0.989, p2=0.012*,p3=0.024*
|
|
|
6 months |
22.09 ± 6.21 |
21.38 ± 5.71 |
21.69 ± 5.94 |
28.28 ± 7.76 |
4.194*
|
0.019*
|
Significance between groups |
|
p1=0.791, p2=0.738, p3=0.970 |
|
|
GLS |
Baseline |
21.19 ± 2.31 |
20.77 ± 2.11 |
23.06 ± 2.15 |
20.15 ± 2.21 |
9.148*
|
<0.001*
|
Significance between groups |
|
p1<0.001*, p2=0.714, p3=0.005*
|
|
|
3 months |
19.85 ± 2.72 |
20.62 ± 2.56 |
18.84 ± 1.84 |
16.25 ± 1.99 |
13.863*
|
<0.001*
|
Significance between groups |
|
p1=0.018*, p2<0.001*,p3=0.033*
|
|
|
6 months |
20.39 ± 2.74 |
21.05 ± 2.53 |
18.77 ± 2.73 |
18.83 ± 2.53 |
5.751*
|
0.005*
|
Significance between groups |
|
p1=0.010*, p2=0.121, p3=0.998 |
|
|